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Despite the favorable prognosis of most patients with Hodgkin’s Lymphoma (HL), 15–20% of patients remain refractory to
chemoradiotherapy, and 20–40% experience relapses following autologous stem cell transplantation (SCT) being used as salvage
approach in this situation. Long-term survival of only 20% was reported for patients who failed this option. As some authors
suggested the presence of a graft versus HL eﬀect, allogeneic SCT was introduced as a further option. Myeloablative strategies were
reported to be able to achieve cure in some younger patients, but high nonrelapse mortality remains a problem. Reduced intensity
conditioning, in turn, was found to be associated with high posttransplant relapse rates. As there is currently no standard in the
management of HL patients who failed autologous SCT, we here review the literature on allogeneic stem cell transplantation in HL
patients with a special focus on the outcomes and risk factors being reported in the largest studies.
1.Introduction
During the last decades, survival of patients with Hodgkin’s
Lymphoma (HL) has substantially improved. To date, 80%–
85% of patients achieve stable remissions [1]. Even in
advanced stages (IIB with large mediastinal tumors and
all stages III-IV according to the Ann Arbor classiﬁca-
tion), more than 80% of patients experience long-term
tumor-free survival. Nevertheless, 15%–20% of HL patients
remain refractory or develop relapse/progression after an
initial chemoradiotherapy. For these patients, high-dose
chemotherapy followed by autologous stem cell support
(HD-SCT) represents a more eﬃcient strategy when com-
pared to conventional chemoradiotherapy [2, 3]. Neverthe-
less, a total of 20–40% patients undergoing chemoradio-
therapy and/or HD-SCT develop relapses during a followup
period of 7 years after treatment [4–9]. Median survival
following HD-SCT failure was reported to range from 6 to
84 months [8–10].
Salvage strategies to improve outcomes for this group
of patients include use of chemotherapy (e.g., gemcitabine-
based regimens) [11], a second HD-SCT [12], and allo-
geneic stem cell transplantation (SCT). Allogeneic SCT for
relapsed/refractory HL patients, ﬁrst reported in the 1980’s
[13, 14], was eﬀective to allow disease control in some
of those, but on the other hand was associated with high
transplant-relatedmortality(TRM)rates[15,16].Therefore,
and based on the assumption of a possible allogeneic graft
versus lymphoma (GvL) eﬀect, it was suggested to introduce
reduced intensity conditioning [17, 18]. Nevertheless, as the
existence of a GvL eﬀect in patients with HL remains contro-
versial,itseemsdiﬃculttoestimatetheroleofallogeneicSCT
for relapsed/refractory HL following HD-SCT. Moreover,
given the rare occurrence of relapsed/refractory HL after
failure of HD-SCT, most studies focusing on allogeneic SCT
were based on limited case series. This paper summarizes
the most relevant studies on the use of allogeneic SCT in
relapsed/refractory HL patients.2 Advances in Hematology
2.IntroductionofAllogeneicSCTinHL
The ﬁrst systematic evaluations of allogeneic SCT in relapsed
HL were published in the 1990’s [16, 19]. For instance,
Gajewski et al. [16] analyzed outcomes for 100 patients
with relapsed/refractory HL. Median age of patients was 24
years (range, 12–44). The majority of patients experienced
advanced disease, and only eleven patients were in remission
at the time of transplantation. The myeloablative regimens
(MAC) were based on combinations of busulfan (16 mg/kg)
and cyclophosphamide (200mg/kg) with or without etopo-
side (20–60mg/kg); or TBI (12Gy) with cyclophosphamide.
The results of the study were disappointing: owing to high
relapse (65%) and nonrelapse mortality rates (61%), 3-year
overall (OS) and disease free survival (DFS) rates were only
21% and 15%, respectively. Similar to previous reports,
the authors observed a lower relapse risk in patients who
developed acute and chronic GVHD, albeit not signiﬁcant
[15, 16, 19–21].
Other studies from the 1990’s suggested that application
of allogeneic strategies in patients with relapsed/refractory
HL was limited by high NRM rates varying from 40%
to 60% [19, 20]. According to such poor results, it was
critically discussed whether myeloablative allogeneic SCT
had a therapeutic potential for this cohort of patients.
Ontheotherhand,Cooneyetal.publishedaninteresting
report on ten relapsed/refractory HL patients (median
age 35 years; range, 21–49) who underwent myeloablative
allogeneic SCT following the BEAM (BCNU, etoposide,
cytarabine, and melphalan) conditioning regimen usually
being reserved for autologous SCT. All patients had failed to
previous HD-SCT. Six patients had chemosensitive disease
with complete or partial remission at the time of allogeneic
SCT, while four were refractory to previous chemotherapy.
The authors observed no treatment-related deaths at 100
days posttransplant, and response was seen in all ten
patients from the study (CR, n = 8; PR, n = 2). In
ﬁve patients, response to allogeneic SCT was associated
with the appearance of chronic GVHD. At the time of the
report, nine patients were alive, of those seven in continuous
complete remission (1 to 21 months from allogeneic SCT),
while only one patient had died due to progression [22].
Althoughthisseriessuggeststhatmyeloablativeconditioning
is an optimal approach for relapsed/refractory HL patients,
the study was limited by the number of enrolled patients
and by short-term median followup of 12 months. Never-
theless, this report might serve as an example that some
m y e l o a b l a t i v es t r a t e g i e ss e e mt ob ea b l et or e d u c eN R Ma s
compared to other intensive conditioning strategies (e.g.,
busulfan/cyclophosphamide, BuCy).
3. Reduced IntensityConditioning
After basic research studies, reduced-intensity conditioning
(RIC) followed by allogeneic SCT has been introduced
for diﬀerent hematologic entities, and has been found
beneﬁcial, for example, for patients who are considered poor
candidates for myeloablative regimens [17, 23, 24]. Based
on the observation of the high NRM in relapsed/refractory
HL patients probably due to the toxicity load of previous
treatments, RIC regimens were as well suggested in the
setting of HL. Indeed, the introduction of allogeneic SCT
following RIC for relapsed/refractory HL patients resulted
in a decreased cumulative incidence of NRM ranging from
11% to 13%. Nevertheless, survival outcomes were relatively
unchanged, as approximately 50% of all patients undergoing
allogeneic SCT after RIC relapsed (Table 1)[ 25–27].
Robinson et al. retrospectively analyzed 285 adult
relapsed/refractory HL patients undergoing diﬀerent RIC
regimens (so far the largest study on the use of RIC in
this setting). The majority of patients (253/285, 89%) were
<45 years and experienced chemosensitive disease; most
had a history of prior HD-SCT. RIC regimens consisted
of ﬂudarabine/melphalan (FluMel), busulfan/ﬂudarabine
(BuFlu), and ﬂudarabine/cyclophosphamide (FluCy) alone
or with thiotepa. Transplantations were performed either
from related (HLA matched, n = 172; mismatched, n = 8)
or unrelated donors (HLA matched, n = 94; mismatched,
n = 11). The early and cumulative 3-year TRM rates were
relatively low (11% and 21%, resp.). Nevertheless, the 5-
year progression rate in this study was increasing up to 59%.
Thus, 3-year OS and progression free survival (PFS) were
29% and 25% only. Acute (grade II-IV) and chronic GvHD
were seen in 34% and 38% of patients, respectively. The
authors observed a trend to lower relapse rate for patients
with GvHD, but there was no impact on PFS or OS [25].
Comparable results were demonstrated by previous studies
on use of RIC regimens in HL patients: though the TRM rate
was lower, overall and disease-free survival did not exceed
50% (Table 1).
Recently, Sarina et al. published the results of a retro-
spective multicenter study on 185 relapsed/refractory HL
patients. In this study, outcomes were correlated with donor
availability. A total of 122 of patients (66%) had a suitable
donor. The patients from the “donor group” experienced
improved 2-year OS and PFS as compared with those from
the “no donor group” (OS: 66% versus 42%, and PFS:
39% versus 14%, P<. 001). The 2-year NRM rate for the
transplanted patients was 13% [28].
Thus, although reduced intensity regimens provide
improvedsurvivaloutcomesandreducedNRMratesascom-
pared to myeloablative strategies in HL patients, increased
relapse or progression rates remain unsolved problems.
4. Arguments for a Graft versus Hodgkin’s
Lymphoma Effect
In some hematologic entities, the existence of a graft versus
malignancy eﬀect has been proven without doubts. For
instance, in chronic myeloid leukemia (CML), or multiple
myeloma, allogeneic SCT as well as donor lymphocytes
infusions (DLIs) being applied due to posttransplant dis-
ease recurrence were signiﬁcantly associated with response
[35–37]. Also in some lymphoproliferative entities, for
example, chronic lymphocyte leukemia (CLL), or follicular
lymphoma (FL), such immunologic eﬀect has been clearly
demonstrated [38, 39]. Whether such eﬀect exists as well in
HL, has been controversially discussed [16, 26, 27, 40], butAdvances in Hematology 3
Table 1: Allogeneic SCT for relapsed/refractory HL patients (HL: Hodgkin’s Lymphoma; no.: number; DLIs: donor lymphocyte infusions;
TRM: transplant-related mortality; DFS: disease-free survival; PFS: progression-free survival; GvL: graft versus lymphoma eﬀect; FM(-A):
ﬂudarabine/melphalan (+alemtuzumab); MAC: myeloablative conditioning regimens; RIC: reduced intensity conditioning regimens; UD:
unrelated donor; MRD: matched related donor; HD: haploidentical donor; NS: not stated).
Reference
No. of
transplant
recipients
Patients with
chemoresistant
HL (no.)
Early TRM Cumulative TRM
(-year)
Relapse
(-year)
DFS/PFS
(-year)
Response to
immuno-therapy
with DLIs
GvL eﬀect
Gajewski et al.
[16] 100 89 13% 61% (3) 65% (3) 15% (3) NS No
Milpied et al.
[19] 45 NS 31% 48% (4) 61% (4) 15% (4) NS Possible
Anderson et al.
[20] 53 NS NS 49% (5) 65% (5) 18% (5) NS Possible
Akpek et al.
[21]
53 28 24%
(chemosensitive)
32%
(chemosensitive) 53% (10) 26% (10) NS Possible
39%
(chemoresistant)
53%
(chemoresistant)
Anderlini et al.
[26] 40 14 5% 22% (1.5) 55% (1.5) 32% (1.5) 3/8 (38%) No
Devetten et al.
[29] 143 67 15% 33% (2) 47% (2) 20% (2) NS NS
Burroughs
et al. [30] 90 16 (MRD) 16% (MRD) 21% (2) (MRD) 56% (2)
(MRD)
23% (2)
(MRD) NS Possible
8 (UD) 0% (UD) 8% (2) (UD) 63% (2)
(UD)
29% (2)
(UD)
6 (HD) 0% (HD) 9% (HD) 40% (2)
(HD)
51% (2)
(HD)
Robinson et al.
[25] 285 72 11% 21% (3) 59% (5) 25% (3) 41/79 (52%) Possible
Claviez et al.
[31] 91 32 NS 26% (5) 44% (5) 30% (5) 2/12 (17%) No
Anderlini et al.
[27] 58 28 7% 15% (2) 55% (2) 32% (2) 6/14 (43%) No
Alvarez et al.
[32] 40 20 13% 25% (1) NS 32% (2) 6/11 (55%) Possible
Peggs et al.
[33]
67 10 (FM-A) NS 7% (2) (FM-A) 54% (3)
(FM-A)
43% (4)
(FM-A)
13/19 (68%)
(FM-A) Possible
19 (FM) 29% (2) (FM) 44% (3)
(FM)
25% (4)
(FM) 6/11 (55%) (FM)
Sureda et al.
[34]
168 43 (MAC) 28% (MAC) 48% (3) (MAC) 30% (3)
(MAC)
20%
(MAC) NS Possible
49 (RIC) 15% (RIC) 24% (3) (RIC) 57% (3)
(RIC) 18% (RIC)
Sarina et al.
[28] 104 36 NS 13% (2) 54% (2) 31% (2) NS Possible
many arguments support this assumption [25, 41]. Alvarez
et al. showed a trend to improved PFS when they compared
HL patients who developed extensive chronic GvHD and
those who did not (71% versus 44%, P = .07) [32].
Therefore, a beneﬁcial eﬀect of DLIs was suggested—for
example, due to the low proliferation rate of HL—even in
case no lymphoma reduction could be achieved by cytotoxic
chemo- or radiotherapy. Beyond that, some larger studies
on allogeneic SCT in patients with relapsed/refractory HL
documented lower relapse rates in case of chronic GvHD
[25, 34]. In conclusion, there is some evidence of a GvL
eﬀect following either allogeneic SCT or DLIs in HL [19–
21, 25, 30, 32–34].
Considering the limitations to conﬁrm a graft versus
malignancy eﬀect in patients with HL, as compared, for
instance, to those with chronic myeloproliferative disorders,
the role of the microenvironment seems to be essential in
this speciﬁc setting. Several reports have described diﬀerent4 Advances in Hematology
intercellular interactions between HRS and nonmalignant
cells, which can lead to immunologic escape [42]. Numer-
ous mechanisms are being discussed: (i) production of
immunosuppressive cytokines (e.g., IL-10, TGFβ,g a l e c t i n1 ,
or prostaglandin E2) by Hodgkin Reed Sternberg cells (HRS)
[42–46]; (ii) expression of the Fas-Ligand (CD95L) [45];
(iii) downregulation of HLA class I antigens; (iv) expression
of HLA-G antigens, which play an important role in the
inhibition of the NK-cell response [47]; (v) expression of
PD-1 (programmed death 1) protein, a negative regulator
on the immune response of T cells and (by it’s ligand)
on HRS cells [48]. Such phenomenons were found to have
an e g a t i v ei m p a c to ns u r v i v a l[ 48, 49]. Also, Steidl et al.
showed a strong association of increased numbers of tumor-
associated macrophages (CD68+) with shortened survival in
patients with classic HL [50]. As follows, novel “targeted”
approaches,suchasCD68+ celldepletionoruseofPD-1/PD-
1L binding antibodies, might be further evaluated in the
setting of HL [51].
5. Reduced IntensityversusMyeloablative:
IsIt Possible to Deﬁne anOptimal
ConditioningStrategy?
As mentioned above, the application of RIC considerably
reduced the incidence of NRM even for patients with poor
prognostic features at the time of allografting. However, the
high relapse rates following allogeneic RIC-SCT remain a
problem. On the other hand, high relapse rates were as well
reported in MAC studies focusing on relapsed/refractory HL
patients who had shown failure to autologous SCT (Table 1).
The largest comparison between MAC and RIC regimens
was performed by Sureda et al. who assessed outcomes
for 168 relapsed/refractory HL patients receiving allografts
(mostly from sibling donors). The majority of patients in
both cohorts were ≤35 years, experienced stage III-IV HL,
had received ≥3 lines of therapy before allogeneic SCT, and a
history of HD-SCT (RIC: 62%, MAC: 41%). More than 50%
of patients from both cohorts had chemoresistant disease.
MAC regimens were based on combinations of cyclophos-
phamide with high-dose TBI (≥8Gy) or busulfan (cum.
16mg/kg). The RIC regimens included BEAM (BCNU,
etoposide, cytarabine, and melphalan) or were based on ﬂu-
darabine combined with an alkylating agent or low-dose TBI
(2–4Gy). Though the early cumulative incidence of acute
GvHD was higher in the MAC group (53% versus 44% for
RIC patients, P = .05), the incidence of chronic GvHD was
similarinbothgroups(MAC:38%;RIC:40%).Althoughthe
patients from the RIC group were more heavily pretreated
than those from the MAC group, the authors observed a
lower cumulative NRM rate in the RIC patients (24% versus
48%, resp., P = .003). The 5-year rate of progression was
signiﬁcantly higher in the RIC when compared to the MAC
cohort (58% versus 32%, resp.; P = .04). After a median
followup of 75 months, 25% of the patients were alive (27%
in the RIC and 23% in the MAC cohorts, resp.). The 5-year
OS (MAC: 22%; RIC: 28%, P = .06) and PFS (MAC: 20%;
RIC: 18%; P = .6) did not diﬀer signiﬁcantly [34]. Thus,
RICregimensaresupposedtoimprovethelong-termOS,but
seem to have limited impact on disease progression as com-
pared with MAC regimens. These results were in accordance
to other studies. Anderlini et al. compared two ﬂudarabine-
based conditioning regimens (FluMel versus FluCy) in
relapsed/refractory HL patients. The authors demonstrated
improved OS and a trend to better PFS at 18 months post-
allograft after the ﬂudarabine/melphalan combination [26].
Sureda et al. showed no suitable evidence of a GvL eﬀect
[34]. These diﬃculties to clearly conﬁrm a graft versus HL
eﬀect might be due to the high proportions of advanced
and chemoresistant disease in the allotransplant setting, as
the development of GvL is more feasible in case of a lower
tumor burden. In this setting, the performance of HD-SCT
being followed by allogeneic SCT allows to reduce the tumor
burdenpriortothedevelopmentofapossiblegraftversusHL
eﬀect [52].
Therefore, it remains diﬃcult to draw ﬁnal conclusions
concerning the most appropriate intensity of conditioning
forrelapsed/refractoryHLpatientswhofailedtoachievecure
by high dose chemotherapy and autologous SCT. There is no
doubt that the use of RIC improves OS in selected patients,
but is linked to high relapse rates.
6. Outcomes According to Different Stem Cell
Sources andDonor Types
Aiming to evaluate whether deﬁnite stem cell source
would provide an immunologic conﬂict being relevant
for a graft versus HL eﬀect, Burroughs et al. evaluated
90 relapsed/refractory HL patients receiving grafts from
diﬀerent donor types. A total of 83 patients (92%) had failed
to prior autologous HD- or syngeneic (allogeneic) SCT.
The preparative regimens consisted of TBI (2Gy) either
alone or combined with ﬂudarabine. For haploidentical SCT,
the authors used a ﬂudarabine/cyclophosphamide regimen
combined with TBI (2Gy). There were no cases of graft
rejection. The 2-year OS was ranging from 53% to 58%
in the diﬀerent groups, without any signiﬁcant diﬀerences.
Strikingly, the early and 2-year NRM rates were lowest
among unrelated and haploidentical graft recipients. The
GvHD rates did not diﬀer with respect to the diﬀerent
donor types. However, the authors reported on a decreased
incidence of relapse in patients receiving allografts from
haploidentical donors, which was suggestive for a graft
versus HL eﬀect [30]. Additionally, better results were
observed in patients from the haploidentical cohort, who
received cyclophosphamide as part of the conditioning. It
was discussed, whether the drug is able to impair the T-
regulatory cells of the microenvironment of Hodgkin/Reed-
Sternberg (H/RS) cells [53–55].
Devetten et al. published the largest report on outcomes
for 143 relapsed/refractory HL patients, all of whom received
allografts from unrelated donors (HLA-matched, n = 110,
77%; mismatched, n = 33, 23%). A total of 127 patients
(89%) had been previously autografted. The main condi-
tioning regimens in this study were as follows: melphalan
(Mel ≤ 150mg/m2; n = 50); busulfan (Bu ≤ 9mg/kg;n =
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(FluCy; n = 23). There was a low early TRM rate of 15%,
but at two years it had increased up to 33%. Thus, the
cumulative TRM rate in this study was higher than that
reported by Robinson et al. (21% at 3 years posttransplant),
most probably due to increased GvHD rates. Although the
relapseratewasmoderatelylowerin thestudy fromDevetten
et al. (47% at 2 years versus 59% at 5 years), the PFS was
similar in both studies (Table 1)[ 25, 29].
Majhail et al. compared safety and eﬃcacy of RIC-SCT
using either unrelated umbilical cord blood (UCB, n =
9) or matched sibling donors (n = 21). Fourteen patients
(67%) had a history of previous HD-SCT. The conditioning
regimens were based on busulfan/ﬂudarabine (BuFlu; n = 8)
or TBI/cyclophosphamide (n = 13). There was no diﬀerence
between the two groups with regards to 2-year PFS, early
TRM, and the incidence of acute or chronic GvHD [56].
In conclusion, donor type and stem cell source seem to
have no signiﬁcant inﬂuence on posttransplant outcomes in
HL patients [29, 30, 56].
7. Outcomes of Allogeneic SCT in Pediatric and
Adolescent PatientsWho Failedto HD-SCT
HD-SCT is increasingly used as salvage therapy also in
pediatric patients with poor-risk HL [57, 58], although
there are no randomized studies demonstrating improved
outcomes for this approach as compared with conventional
chemoradiotherapy. Information regarding the role of allo-
geneicSCTforHLinthepediatricpopulationisverylimited.
Children undergoing allogeneic SCT have been occasionally
included in series of adult patients [16, 21, 34]. Series
focusing exclusively on pediatric patients were limited to
fewer than 10 patients [40].
Claviez et al. published the largest series in pediatric or
adolescentpatientsreceivingallogeneicSCT(n = 91).Atotal
of 40 patients (44%) failed to prior HD-SCT. Forty patients
(44%) received myeloablative conditioning, in most cases
basedonbusulfan/cyclophosphamide(BuCy)andTBIalone,
or combined with etoposide or cytarabine. RIC regimens
were performed in 51 patients (56%) and consisted of com-
binations of ﬂudarabine with either melphalan (FluMel),
busulfan (BuFlu), cyclophosphamide (FluCy), thiotepa, or
low-dose TBI. The relapse rate was 34% in the MAC and
54% in the RIC cohort (P = .01). However, this had
to be seen with regard to the diﬀerent risk proﬁles, as
patients with RIC had longer intervals between diagnosis
and allogeneic SCT, had failed more lines of chemotherapy,
includingHD-SCT,andweresigniﬁcantlyolderthanpatients
who underwent myeloablative conditioning. Primary graft
failures occurred in ﬁve of 91 patients (6%), but in four cases
stable engraftment was achieved after a second allogeneic
SCTfollowingRICconditioning.Atotalof21patients(23%)
died due to transplant-related causes. The frequencies of
grade II-IV acute and chronic GvHD were 25% and 36%,
respectively. Although in the early posttransplant period
there was no diﬀerence in the relapse risk between the MAC
andRICcohorts,itbecameapparentthattherelapseriskhad
signiﬁcantly been increasing in patients who received RIC
starting 9 months following transplantation. In addition,
these patients had a signiﬁcantly lower 3-year PFS [31].
Thus,morevigorous(notnecessarilyfullymyeloablative)
conditioning might represent a viable option to reduce the
high relapse rates being seen in children and adolescents who
tolerate aggressive chemotherapy as part of the conditioning
regimen much better than older patients.
8. T-Cell Depletion
In vivo eradication of T cells during conditioning before
allogeneic SCT was found to decrease the probability of
GvHD [59, 60]. In case of HL, some T-cell depleting agents
(e.g., monoclonal antibody alemtuzumab) might directly
aﬀect the tumor through the eradication of T cells, creating
the tumor-supporting microenvironment [61]. Based on
these assumptions, Peggs et al. investigated the role of in
vivo T depletion in 67 relapsed/refractory HL patients most
of whom had previously undergone HD-SCT. They used a
ﬂudarabine/melphalan (FluMel) regimen either with (n =
31) or without (n = 36) alemtuzumab (targeting CD52
positive cells). The cumulative TRM rate at two years was 7%
in the alemtuzumab cohort and 29% in the “FluMel only”
group[33].Itisdiﬃculttodeterminewhethereitherstrategy
had a signiﬁcant inﬂuence on the relapse risk. Nevertheless,
both the 3-year cumulative incidence of relapse (54% versus
44%) and 3-year PFS (43% versus 25%) were higher in
patients with the FluMel/alemtuzumab regimen. This might
have been associated to use of DLIs in the relapsed patients.
Further, the authors conﬁrmed the observation, that the
inclusion of monoclonal antibodies (e.g., alemtuzumab
or rituximab) into the preparative regimen signiﬁcantly
reduced both acute and chronic GvHD [62, 63]. In addition,
thereseemedtobeatrendtolongerdurationoftheresponses
in the alemtuzumab cohort (median, 33 months versus <12
months). Thus, the use of in vivo T-cell depletion with
alemtuzumab did not seem to inhibit the GvL eﬀect. In
contrary, alemtuzumab might have a direct eﬀect on the
tumor thereby improving survival rates [33].
9.AlternativeStrategies
For those patients who experience relapse of HL after
allogeneic SCT, or who are no candidates for allogeneic
SCT, alternative therapeutic approaches might be applied.
These include the use of conventional or novel chemother-
apeutic compounds (e.g., gemcitabine, pentostatin) [64–
71], monoclonal antibody-based approaches (e.g., anti-
CD20, anti-CD30, or radiolabeled antibodies) [72–76], use
of histone deacetylase inhibitors (e.g., vorinostat) [77, 78],
immunomodulatory drugs (e.g., thalidomide and lenalido-
mide) [79, 80], or their combinations [81, 82]. In addition,
a pivotal trial with brentuximab—a novel agent consisting
of an anti-CD30 monoclonal antibody and monomethyl
auristatin E, an antimitotic agent—was recently completed
[83]. The overall response (OR) rate in the cited studies var-
ied from 25% to 76%. The most eﬀective compounds were
represented by gemcitabine (OR: 22%–76%), vinca alkaloids6 Advances in Hematology
(OR:46%–59%),andimmunomodulatorydrugs(OR:33%–
50%). Despite the relatively high response rate in some
cases,responseswerenotstable(medianduration6months).
Nevertheless, Bartlett et al. reported on maximal progression
free survival of 58 months after use of gemcitabine-based
regimens(gemcitabine,vinorelbine,andpegylatedliposomal
doxorubicin) [65].
In conclusion, nowadays there is no alternative to allo-
geneic SCT strategy that allows to achieve long-time survival
inrelapsed/refractoryHLpatients.Therefore,allogeneicSCT
most probably will continue to play an important role in this
setting.
10. Conclusions
Although HL can be cured in the majority of cases with
conventional chemoradiotherapy as ﬁrst-line and HD-SCT
as second-line strategies, there are no standard options for
patients relapsing following autografting. Although there
is no doubt that allogeneic SCT is an important and in
some cases even curative strategy for relapsed/refractory
HL patients, its role in this speciﬁc setting remains to
be more clearly deﬁned. First, transplantation rates are
limited, and so is the number of large allotransplant studies
focusing solely on this entity. Proper indications for this
procedureandeligibleselectioncriteriaareurgentlyrequired
considering the risks, associated with this approach, espe-
cially when myeloablative conditioning is being performed
[16, 20]. Though some studies suggested the development
of a graft versus HL eﬀect [19–21, 25, 30, 32, 33], its
existence remains still unproven. As the donor type does
not seem to have a dramatic impact on the outcomes, the
intensity of conditioning represents the most important
transplant-associated parameter in this term. The intro-
duction of RIC in the transplant setting improved NRM
rates, but the incidence of relapse was high. Therefore,
the question about an optimal intensity of conditioning
in relapsed/refractory HL patients remains open. Heavily
pretreated patients and patients with comorbidities should
preferably undergo reduced conditioning, whereas some
younger patients might have a beneﬁt from myeloablative
(e.g., BuCy) or less intensiﬁed conventional regimens (e.g.,
BEAM) due to the lower relapse rates [22, 31]. The use
of in vivo T-cell depletion might contribute to better
survival outcomes [33]. Though the present role of the
allogeneic SCT in relapsed/refractory HL patients is not
deﬁned, some retrospective studies have already shown a
realistic clinical beneﬁt of this approach as compared to
conventional chemotherapy [28]. In this setting, prospective
multicenter study are needed to standardize the indication
and the time point of allogeneic SCT in therapeutic algo-
rithms for patients with relapsed or refractory Hodgkin
lymphoma.
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